Semaglutide is a hypoglycemic drug developed by Novo Nordisk. The drug is a glucagon-like peptide-1

On December 9, 2024, Criantics announced that the FDA has accepted the submission of a New Drug Appl

The research and development and market layout of domestic HPV vaccines are in a stage of rapid deve

On November 4, Journey Medical announced that the FDA has approved Emrosi™ (Minocycline hydrochlorid

Recently, Roche (Roche) researchers published in the international top medical journal Nature Medici

On September 6, GlaxoSmithKline (GSK) announced positive results from the Phase III MATINEE study of

On June 7, GlaxoSmithKline (GSK) announced that the FDA approved Arexvy, a recombinant respiratory s

On May 13, Takeda announced that it has entered into A worldwide exclusive option and license agreem

On April 1, 2024, Astrazeneca announced the FDA approval of its "first-in-class" oral smal

Recent studies have shown that by improving the linking technology and developing novel drug carrier